Resistance of beta-endorphin to dexamethasone inhibition in parkinson's and alzheimer's diseases

References

• Airaghi L., Truci G., Catania A., Manfredi M. Q., Canal N., Franceschi M. Lack of evidence for abnormalities of Cortisol secretion in patients with Alzheimer's disease. XlVth World Congress of Neurology, New Delhi, October 22–27, 1989, C403
   Google Scholar
• Balldin J., Gottfries C, Karlsson I., Lindstedt G., Langstrom G., Walinder J. Dexamethasone suppression test and serum prolactin in dementia disorders. British Journal of Psychiatry 1983; 143: 277–281
   PubMed Web of Science ®Google Scholar
• Berkenbosch F., Vermes I., Tilders J. H. The beta-adrenoceptor-blocking drug propranolol prevents secretion of immunoreactive beta-endorphin and alfa-melanocyte-stimulating hormone in response to certain stress stimuli. Endocrinology 1984; 115: 1051–1059
   PubMedGoogle Scholar
• Brambilla F., Genazzani A. R., Facchinetti F., Parrini D., Petraglia F., Sacchetti E., Scarone S., Guastalla A., ĎAntona N. Beta-Endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders. Psychoneuroendocrinol-ogy 1981; 6: 321–330
   PubMedGoogle Scholar
• Carnes M., Smith J. C., Kalin N., Bauwens S. F. Effects of chronic medical illness and dementia on the dexamethasone suppression test. Journal of American Geriatric Society 1983; 31: 269–271
   PubMedGoogle Scholar
• Castro P., Toscano Aguilar M. Dexamethasone suppression test in demented patients and control aged subjects. Senile dementias: early detection, A. Bes. John Libbey Eurotext, Paris 1986; 561–563
   Google Scholar
• Christie J. E., Brown N. S., Dick H., Rosie R., Sanches-Watts G. Neuroendocrine studies in Alzheimer's disease. Interdisciplinary Topics in Gerontology 1985; 19: 131–142
   Google Scholar
• Conte-Devolx B., Pflster B., Viallet F., Rey M., Conte-Devolx J. La fonction endocrine ante-hypophysaire dans la maladie de Parkinson. La Presse Medicate 1987; 16: 566–568
   PubMedGoogle Scholar
• Cross A. J., Crow T. J., Perry E. K., Blessed G., Tomlinson B. E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. British Medical Journal 1981; 282: 93–94
   PubMed Web of Science ®Google Scholar
• Facchinetti F., Petraglia F., Nappi G., Parrini D., Martignoni E., Antoni G., Genazzani A. R. Different pattern of central and peripheral beta EP, beta LPH and ACTH throughout life. Peptides 1983; 4: 469–474
   PubMedGoogle Scholar
• Facchinetti F., Petraglia F., Sances G., Garuti C, Tosca P., Nappi G., Genazzani A. R. Dissociation between CSF and plasma bcta-endorphin in major depressive disorders: evidence for a different regulation. Journal of Endocrinological Investigation 1986; 9: 11–14
   PubMedGoogle Scholar
• Facchinetti F., Giovannini C, Petraglia F., Barletta C, Comitini G., Genazzani A. R. Plasma bela-endorphin resistance to dexamethasone suppression in obese patients. Journal of Endocrinological Investigation 1988; II: 119–123
   Google Scholar
• Foley K. M., Kourides I. A., Inturrisi C. E., Kaiko R. F., Zaroulis C. G., Posner J. B., Houde R. W., Lee C. H. Beta-endorphin: analgesic and hormonal effects in humans. Proceedings of the National Academy of Sciences USA 1979; 76: 5377–5381
   PubMed Web of Science ®Google Scholar
• Folstein M., Folstein S., McHugh P. Mini-Mental State. Journal of Psychiatric Researches 1975; 12: 189–198
   PubMed Web of Science ®Google Scholar
• Franceschi M., Cecchetto R., Pancrai A. E., Truci G., Smirne S., Canal N. Plasma beta-endorphin and bcta-lipotropin in patients with Parkinson's disease. Clinical Neuroendocrinology 1986; 6: 549–555
   Google Scholar
• Franceschi M., Perego L., Ferim-Strambi L., Smirne S., Canal N. Neuroendocrinological function in Alzheimer's disease. Neuroendocrinology 1988; 48: 367–370
   PubMedGoogle Scholar
• Genazzani A. R., Facchinetti F., Pintor C, Puggioni R., Parrini D., Petraglia F., Bagnoli F., Corda R. Proopiomelanocortin-related peptide plasma levels throughout prepuberty and puberty. Journal of Clinical Endocrinology & Metabolism 1983; 57: 56–61
   PubMedGoogle Scholar
• Genazzani A. R., Petraglia F., Facchinetti F., Golinelli S., OltraMarić P., Santoro V., Volpe A. Evidences for a dopamine-regulated peripheral source of circulating beta-endorphin. Journal of Clinical Endocrinology & Metabolism 1988; 66: 279–282
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Havenmann U., Winkler M., Gene E., Kuschinsky K. Opioid actions on motility: possible actions on GABA-ergic and dopaminergic neurons. Brain Research Bulleltin 1980; 5: 891–896, (Suppl. 2)
   Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Imura H., Nakai Y., Nakao K., Oki S., Tanaka I., Jngami H., Yoshimasa T., Tsukada T., Ikeda Y., Suda M., Sakamoto M. Biosynthesis and distribution of opioid peptides. Journal of Endocrinological Investigation 1983; 6: 139–149
   PubMed Web of Science ®Google Scholar
• Javoy-Agid F., Ruberg M., Pique L., Bertagna X., Taquet H., Studler J. M., Cesselin F., Epelbaum I., Agid Y. Biochemistry of the hypothalamus in Parkinson's disease. Neurology 1984; 34: 672–675
   PubMed Web of Science ®Google Scholar
• Kawamura T., Kinoshita M., Iwasaki Y., Nemoto H. Low-dose dexamethasone suppression test in Japanese patients with Parkinson's disease. Journal of Neurology 1987; 234: 264–265
   PubMed Web of Science ®Google Scholar
• May C, Rapoport S. I., Tomai T. P., Chrousos G. P., Gold P. W. Cerebrospinal fluid concentrations of corticotropin-relcasing hormone (CRH) and corticotropin (ACTFf) are reduced in patients with Alzheimer's disease. Neurology 1987; 37: 535–538
   PubMed Web of Science ®Google Scholar
• Martignoni E., Petraglia F., Bono G., Costa A., Genazzani A. R., Nappi G. Evaluation of CSF corticotropin releasing factor (CRF) and plasma Cortisol levels in patients with dementia of the Alzheimer type. Journal of Endocrinological Investigation 1989; 12: 176, (Suppl. 2)
   Google Scholar
• McKhann G., Drachtnan D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of AD: report of the NINCDS-ADRDA work group under the auspices of Health and Human Service Task Force on AD. Neurology 1984; 34: 939–944
   PubMed Web of Science ®Google Scholar
• Millington W. R., O'Donohue T. L., Mueller G. P. Dopaminergic agents selectively alter the post-translational processing of beta-endorphin in the intermediate pituitary of the rat. Journal of Pharmacology and Experimental Therapeutics 1987; 243: 160–170
   PubMed Web of Science ®Google Scholar
• Nappi G., Petraglia F., Martignoni E., Facchinetti F., Bono G., Genazzani A. R. Beta-endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology 1985; 35: 1371–1374
   PubMed Web of Science ®Google Scholar
• Nappi G., Sinforiani E., Martignoni E., Petraglia F., Facchinetti F., Rossi F., Genazzani A. R. Aging brain and dementias: changes in central opioids. European Neurology 1988a; 28: 217–220
   PubMedGoogle Scholar
• Nappi G., Martignoni E., Sinforiani E., Facchinetti F., Genazzani A. R. Acetyl-carnitine normalizes pituitary-adrcnocortical hyperactivity in pathological ageing brain. Medical Science Research 1988b; 16: 291–292
   Google Scholar
• Pique L., Jegon S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vandry H., Luton J. P. Proopiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Raskind M., Peskind E., Rivard M. Dexamethasone suppression test and Cortisol and circadian rhythm in primary degenerative dementia. American Journal of Psychiatry 1982; 139: 1468–1471
   PubMed Web of Science ®Google Scholar
• Rivier C, Brownstein M., Spiess J., Rivier J., Vale W. Tn vivo corticotropin-releasing factor induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology 1982; 110: 272–278
   PubMed Web of Science ®Google Scholar
• Sandyk R. The endogenous opioid system in neurological disorders of the basal-ganglia. Life Science 1985; 37: 1655–1663
   PubMed Web of Science ®Google Scholar
• Sandyk R. Pro-opiomelanocortin (POMC) processing in Parkinson's disease. International Journal of Neuroscience 1989; 46: 201–204
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P., Bamford C. R. The hypothalamus in Parkinson disease. The Italian Journal of Neurological Sciences 1987; 8: 227–234
   PubMedGoogle Scholar
• Sapolsky R. M., Krey L. C., McEwen B. S. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocrine Reviews 1986; 7: 284–301
   PubMed Web of Science ®Google Scholar
• Smith A. I., Funder J. W. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocrine Reviews 1988; 9: 159–179
   PubMed Web of Science ®Google Scholar
• Stein L., Belluzzi J. D. Brain endorphins: possible role in reward and memory formation. Federation Proceedings 1979; 38: 2468–2473
   PubMedGoogle Scholar
• Sulkava R., Erkinjuntti T., Laatidainen T. CSF beta-endorphin and beta-lipotrophin in Alzheimer's disease and multi-infarct dementia. Neurology 1985; 35: 1057–1058
   PubMed Web of Science ®Google Scholar
• Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394–1397
   PubMed Web of Science ®Google Scholar